Lord Abbett & CO. LLC Invests $5.80 Million in Artivion, Inc. (NYSE:AORT)

Lord Abbett & CO. LLC acquired a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 217,800 shares of the company's stock, valued at approximately $5,798,000. Lord Abbett & CO. LLC owned approximately 0.52% of Artivion at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in AORT. nVerses Capital LLC acquired a new position in shares of Artivion during the second quarter valued at about $28,000. Quarry LP grew its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after purchasing an additional 820 shares during the period. RiverPark Advisors LLC purchased a new position in shares of Artivion during the 2nd quarter valued at approximately $55,000. RW Investment Management LLC acquired a new position in shares of Artivion in the 2nd quarter valued at $219,000. Finally, Intech Investment Management LLC purchased a new stake in Artivion during the second quarter worth $253,000. 86.37% of the stock is currently owned by institutional investors.

Insider Transactions at Artivion

In other Artivion news, VP Andrew M. Green sold 7,618 shares of the company's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company's stock, valued at $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Amy Horton sold 12,430 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company's stock, valued at $3,664,912.02. The trade was a 8.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,447 shares of company stock worth $925,424 in the last ninety days. Insiders own 8.10% of the company's stock.

Wall Street Analyst Weigh In

AORT has been the topic of a number of analyst reports. Stifel Nicolaus raised their target price on Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, September 13th. Oppenheimer upped their target price on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Needham & Company LLC reissued a "buy" rating and issued a $34.00 price target on shares of Artivion in a research note on Monday, December 9th. Finally, JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $31.80.

Artivion Price Performance

AORT stock traded down $0.06 during midday trading on Tuesday, reaching $28.90. The stock had a trading volume of 213,976 shares, compared to its average volume of 226,487. The company's fifty day simple moving average is $27.76 and its 200 day simple moving average is $26.27. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -1,432.50 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.45.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.